Charter Medical (LDL) Receives CE Mark Clearance for Next Generation Cell Freeze Cryogenic Stem Cell Storage

Charter Medical, Ltd., a Lydall subsidiary, (NYSE: LDL) announced today that it received CE Mark approval on its next generation Cell Freeze® Cryogenic Storage Containers for Hematopoietic Progenitor Cells (HPC's). The issuance of the approval by European regulators allows Charter Medical to begin marketing and selling the newly designed and expanded product offering for cryogenic storage, preservation, and transfer of HPC's in Europe. These next generation storage containers offer a broad size range from 50 mL to 750 mL and have excellent durability when frozen at ultralow (-196°C) temperatures.

---

Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!

You May Also Be Interested In

• Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
• Bayer, Onyx Pharma (ONXX) Say Nexavar Missed Primary Endpoint in Phase 3
• Catalyst Pharmaceutical (CPRX) Reports Encouraging Data from CPP-115 Phase Ia

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter